The biotech sector has historically offered attractive returns for investors. According to Mutants Investments' data, their biotech investments have achieved average annual returns between 15-25% over the past 5 years. However, there is significant volatility and drawdown risk associated with investing in early-stage biotech companies.

Mutants aims to generate consistent monthly returns in the range of 3-15% by diversifying investments across a portfolio of 15-25 private and public biotech companies. This strategy is designed to mitigate risk while still targeting above average returns. The exact return rate fluctuates month-to-month based on portfolio performance.

In periods of biotech sector growth and bull markets, monthly returns on the higher end of the projected range are possible. However, extended drawdowns where returns dip below 3% or even become negative are also a possibility during bear markets or industry downturns. Mutants' investment team actively manages the portfolio to minimize drawdowns.

Past performance does not guarantee future returns. The highly complex nature of drug development means there are no guarantees for any individual investment. Careful due diligence and diversification across multiple companies is key to managing risk. Investors should be cautious of any investments promising fixed high returns in this traditionally volatile sector.

Gene Therapy
Synthetic biology
Bioinformatics
Drug Discovery
Genetic Engineering

To support its growth, Mutants Investment aims to double its investment team over the next 3 years. It will hire additional analysts and associates with scientific domain expertise and venture capital experience. Expanding its talent pool will allow Mutants Investment to undertake more deals while maintaining rigorous due diligence.